









Markets
/
Stocks
/
nasdaq-lxrx
/

Lexicon Pharmaceuticals Inc

LXRX

1.250USD

-0.180-12.59%

Close 11/07, 16:00（ET）Quotes delayed by 15 min

457.23MMarket Cap

LossP/E TTM



Lexicon Pharmaceuticals Inc

1.250

-0.180-12.59%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Lexicon Pharmaceuticals Inc

Currency: USD Updated: 2025-11-07

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Lexicon Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

71 / 407

Overall Ranking

188 / 4614

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 5 analysts

Buy

Current Rating

2.880

Target Price

+130.40%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Lexicon Pharmaceuticals Inc Highlights

StrengthsRisks

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The Company pipeline includes INPEFA (sotagliflozin), LX9211, and LX9851. Sotagliflozin is an orally delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. LX9211 is an orally delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. The Company is conducting preclinical development of LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and tool for weight management.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 22260.43% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 31.08M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 31.08M.

Undervalued

The company’s latest PE is -6.87, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 261.46M shares, decreasing 16.39% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 420.70K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.62.

Financial Health

Currency: USD Updated: 2025-11-07

The company's current financial score is 8.66, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 28.87M, representing a year-over-year increase of 1652.64%, while its net profit experienced a year-over-year increase of 106.09%.

Score

Industry at a Glance

Previous score

8.66

Change



Financials

5.50

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.81

Key Metrics

Free cash flow

No Data

Lexicon Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2025-11-07

The company’s current valuation score is 5.98, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -6.87, which is -100.00% below the recent high of 0.00 and 0.00% above the recent low of -6.87.

Score

Industry at a Glance

Previous score

5.98

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 71/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-07

The company’s current earnings forecast score is 7.60, which is lower than the Biotechnology & Medical Research industry's average of 8.00. The average price target for Lexicon Pharmaceuticals Inc is 1.90, with a high of 6.00 and a low of 1.00.

Score

Industry at a Glance

Previous score

7.60

Change

Support & Resistance

No Data

Analyst Rating

Based on 5 analysts

Buy

Current Rating

2.880

Target Price

+130.40%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Lexicon Pharmaceuticals Inc

LXRX

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-07

The company’s current price momentum score is 6.43, which is lower than the Biotechnology & Medical Research industry's average of 6.46. Sideways: Currently, the stock price is trading between the resistance level at 1.49 and the support level at 1.09, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.68

Change

-0.25

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.035

Neutral

RSI(14)

41.663

Neutral

STOCH(KDJ)(9,3,3)

32.568

Neutral

ATR(14)

0.086

Low Volatility

CCI(14)

-169.098

Sell

Williams %R

80.000

Sell

TRIX(12,20)

-0.092

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

1.350

Sell

MA10

1.356

Sell

MA20

1.402

Sell

MA50

1.316

Sell

MA100

1.191

Buy

MA200

0.897

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-07

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 5.16. The latest institutional shareholding proportion is 71.95%, representing a quarter-over-quarter decrease of 6.47%. The largest institutional shareholder is The Vanguard, holding a total of 8.85M shares, representing 2.44% of shares outstanding, with 10.48% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Artal International S.C.A.

136.18M

Invus Public Equities Advisors, LLC

38.92M

Fidelity Management & Research Company LLC

38.14M

+10.41%

The Vanguard Group, Inc.

Star Investors

8.85M

-7.39%

Ulys, L.L.C.

5.45M

Schonfeld Strategic Advisors LLC

4.58M

-44.28%

BlackRock Institutional Trust Company, N.A.

3.17M

-65.57%

Sessa Capital

3.00M

CIBC Private Wealth Management

2.45M

+9.39%

Geode Capital Management, L.L.C.

2.38M

-35.55%

Risk Assessment

Currency: USD Updated: 2025-11-07

The company’s current risk assessment score is 3.76, which is higher than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 0.97. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.